$0.44
4.34% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Century Therapeutics Inc Classifications & Recommendation:

Buy
88%
Hold
13%

Century Therapeutics Inc Price Target

Target Price $5.43
Price $0.44
Potential
Number of Estimates 7
7 Analysts have issued a price target Century Therapeutics Inc 2026 . The average Century Therapeutics Inc target price is $5.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Century Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Century Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Century Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 6.59 38.17
194.20% 479.26%
Net Margin -2,097.15% -125.93%
76.21% 94.00%

8 Analysts have issued a sales forecast Century Therapeutics Inc 2025 . The average Century Therapeutics Inc sales estimate is

$38.2m
Unlock
. This is
479.26% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$109m 1,557.06%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $6.6m 194.20%
2025
$38.2m 479.26%
Unlock
2026
$5.5m 85.53%
Unlock
2027
$3.7m 32.36%
Unlock
2028
$3.8m 1.38%
Unlock
2029
$21.6m 469.98%
Unlock

1 Analyst has issued a net profit forecast Century Therapeutics Inc 2025 . The average Century Therapeutics Inc net profit estimate is

$-48.1m
Unlock
. This is
65.43% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-48.1m 65.43%
Unlock
, the lowest is
$-48.1m 65.43%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-138m 30.00%
2025
$-48.1m 65.22%
Unlock
2026
$-94.4m 96.42%
Unlock
2027
$-101m 7.28%
Unlock
2028
$-90.1m 11.02%
Unlock
2029
$-81.6m 9.52%
Unlock

Net Margin

2024 -2,097.15% 76.21%
2025
-125.93% 94.00%
Unlock
2026
-1,709.96% 1,257.87%
Unlock
2027
-2,711.95% 58.60%
Unlock
2028
-2,380.25% 12.23%
Unlock
2029
-377.83% 84.13%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.61 -0.56
30.00% 65.22%
P/E negative
EV/Sales negative

1 Analysts have issued a Century Therapeutics Inc forecast for earnings per share. The average Century Therapeutics Inc EPS is

$-0.56
Unlock
. This is
65.43% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.56 65.43%
Unlock
, the lowest is
$-0.56 65.43%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.61 30.00%
2025
$-0.56 65.22%
Unlock
2026
$-1.10 96.43%
Unlock
2027
$-1.18 7.27%
Unlock
2028
$-1.05 11.02%
Unlock
2029
$-0.95 9.52%
Unlock

P/E ratio

Current -0.28 84.53%
2025
-0.82 192.86%
Unlock
2026
-0.42 48.78%
Unlock
2027
-0.39 7.14%
Unlock
2028
-0.44 12.82%
Unlock
2029
-0.48 9.09%
Unlock

Based on analysts' sales estimates for 2025, the Century Therapeutics Inc stock is valued at an EV/Sales of

-2.51
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -14.56 122.28%
2025
-2.51 82.73%
Unlock
2026
-17.38 591.29%
Unlock
2027
-25.69 47.84%
Unlock
2028
-25.34 1.36%
Unlock
2029
-4.45 82.46%
Unlock

P/S ratio

Current 5.99 95.05%
2025
1.03 82.74%
Unlock
2026
7.15 591.29%
Unlock
2027
10.57 47.85%
Unlock
2028
10.43 1.36%
Unlock
2029
1.83 82.46%
Unlock

Current Century Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 03 2025
Guggenheim
Locked
Locked
Locked Mar 28 2025
Chardan Capital
Locked
Locked
Locked Mar 24 2025
Guggenheim
Locked
Locked
Locked Mar 21 2025
Piper Sandler
Locked
Locked
Locked Mar 20 2025
Guggenheim
Locked
Locked
Locked Jan 22 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 22 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 03 2025
Locked
Guggenheim:
Locked
Locked
Mar 28 2025
Locked
Chardan Capital:
Locked
Locked
Mar 24 2025
Locked
Guggenheim:
Locked
Locked
Mar 21 2025
Locked
Piper Sandler:
Locked
Locked
Mar 20 2025
Locked
Guggenheim:
Locked
Locked
Jan 22 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 22 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today